This research addresses the urgent need for broad-spectrum antivirals amid rising pandemics and drug resistance. It focuses on carbocyclic nucleosides—stable, enzyme-resistant molecules that inhibit viral replication via RdRp and host targets such as SAH hydrolase and IKKα—active against RNA and DNA viruses. A diverse library of noraristeromycin analogs is synthesized and optimized, with in vitro and in vivo evaluation of potency, selectivity, and pharmacokinetics. Preliminary data show (-)-5’-noraristeromycin is highly active against SARS-CoV-2, CMV, and other viruses with minimal toxicity, further improved by fluorine substitutions. 31 Publication and over 40 patents, with 45+ years of experience.